Please check your internet connection and try again.
# Sodium Phosphate Enema
## Overview
Sodium phosphate enema is a hypertonic saline solution used as a stimulant laxative for bowel cleansing prior to diagnostic procedures or surgical procedures, and for the relief of occasional constipation.
## Primary Indications
* Bowel preparation for colonoscopy or surgery.
* Relief of occasional constipation.
## Adult Dosing
* **Bowel Preparation:** Typically, one 4.5 fl oz (133 mL) enema administered rectally within 5 minutes. May be repeated as directed by physician. Administration instructions should be followed closely to ensure efficacy and safety.
* **Constipation:** Typically, one 2.25 fl oz (66 mL) enema administered rectally. Maximum dose is one 4.5 fl fl oz (133 mL) enema in 24 hours.
## Pediatric Dosing
* **Constipation:**
* Ages 2 to <6 years: 1.125 fl oz (33 mL) rectally once every other day as needed.
* Ages 6 to <12 years: 2.25 fl oz (66 mL) rectally once every other day as needed.
* Age 12 years and older: Adult dose.
* **Bowel Preparation:** Use in children is generally not recommended due to increased risk of electrolyte disturbances and dehydration. If used, dosing should be based on specific pediatric protocols, which are not universally established and require careful consideration of the child's weight and renal function. Consult pediatric guidelines.
## Dose Adjustments
No specific dose adjustments are routinely recommended for hepatic or renal impairment; however, caution is advised, and monitoring for electrolyte imbalances is crucial, especially in patients with compromised kidney function.
## Contraindications
* Congenital or acquired megacolon.
* Heart failure, congestive heart failure.
* Abdominal pain, nausea, vomiting, or other symptoms of appendicitis, fecal impaction, intestinal obstruction, or undiagnosed abdominal distress.
* Renal impairment (CrCl <30 mL/min).
* Use in children under 2 years of age.
* Patients on medications that affect sodium or fluid balance.
* Patients with conditions that increase the risk of electrolyte disturbances (e.g., ileostomy or colostomy).
## Adverse Effects
* **Common:** Abdominal discomfort, cramping, nausea, vomiting, rectal irritation, bloating.
* **Serious:**
* **Hyperphosphatemia:** Can lead to hypocalcemia, tetany, cardiac arrhythmias, and renal damage. This is a significant risk, especially with repeated doses, in patients with renal impairment, or in young children.
* **Hyponatremia:** Can lead to seizures, especially in children.
* **Dehydration.**
* **Electrolyte imbalances:** Including hypokalemia, hyperkalemia, and hypocalcemia.
* **Arrhythmias.**
* **Renal toxicity.**
## Key Drug Interactions
* **Diuretics:** Increased risk of electrolyte imbalance and dehydration.
* **ACE inhibitors and ARBs:** Increased risk of hyperkalemia.
* **Lithium:** Increased risk of lithium toxicity due to altered renal excretion.
* **Drugs affecting renal function:** May exacerbate electrolyte imbalances.
## Monitoring
* **Electrolytes:** Particularly serum phosphate, calcium, sodium, and potassium levels, especially in patients with risk factors for electrolyte disturbances, renal impairment, or after repeated doses.
* **Renal function:** Monitor BUN and creatinine.
* **Hydration status.**
* **Cardiac rhythm:** In patients with risk factors for arrhythmias.
## Clinical Pearls
* This product is a hypertonic solution and draws water into the bowel.
* Ensure patients understand and follow the administration instructions precisely to minimize risks.
* Avoid use in patients with any contraindications due to the high risk of serious adverse events, especially electrolyte abnormalities.
* The risk of serious hyperphosphatemia and subsequent complications is significant. Strict adherence to dosing and contraindications is paramount.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the official prescribing information for the most up-to-date and comprehensive details. Local protocols and individual patient factors may necessitate deviations from general guidelines.*
